Skip to Content
Merck
  • Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein.

Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein.

Nature communications (2017-06-29)
Laura A Laviolette, Julien Mermoud, Isabel A Calvo, Nicholas Olson, Myriam Boukhali, Ortrud K Steinlein, Elisabeth Roider, Elke C Sattler, Dachuan Huang, Bin Tean Teh, Mo Motamedi, Wilhelm Haas, Othon Iliopoulos
ABSTRACT

Germline mutations in the Folliculin (FLCN) tumour suppressor gene result in fibrofolliculomas, lung cysts and renal cancers, but the precise mechanisms of tumour suppression by FLCN remain elusive. Here we identify Rab7A, a small GTPase important for endocytic trafficking, as a novel FLCN interacting protein and demonstrate that FLCN acts as a Rab7A GTPase-activating protein. FLCN-/- cells display slower trafficking of epidermal growth factor receptors (EGFR) from early to late endosomes and enhanced activation of EGFR signalling upon ligand stimulation. Reintroduction of wild-type FLCN, but not tumour-associated FLCN mutants, suppresses EGFR signalling in a Rab7A-dependent manner. EGFR signalling is elevated in FLCN-/- tumours and the EGFR inhibitor afatinib suppresses the growth of human FLCN-/- cells as tumour xenografts. The functional interaction between FLCN and Rab7A appears conserved across species. Our work highlights a mechanism explaining, at least in part, the tumour suppressor function of FLCN.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal ANTI-FLAG® M2 antibody produced in mouse, 1 mg/mL, clone M2, affinity isolated antibody, buffered aqueous solution (50% glycerol, 10 mM sodium phosphate, and 150 mM NaCl, pH 7.4)
Millipore
Anti-FLAG® M2 Magnetic Beads, affinity isolated antibody
Sigma-Aldrich
Anti-EGFR (cytoplasmic domain) Antibody, clone 8G6.2, clone 8G6.2, from mouse